Serena Williams’ return to professional tennis has reignited a wider discussion about the role of medication in elite sport. After the 23-time Grand Slam champion revealed that she had used weight-loss medication following the birth of her second child, renewed questions emerged around the rules governing therapeutic treatments and what substances players are allowed to use while competing.
The debate intensified because Williams’ decision was not questioned while she was away from the tour, but became a topic of conversation once she announced her comeback during the grass-court season. The situation prompted fresh attention toward the balance between protecting athletes’ health and ensuring that approved treatments cannot provide an unfair competitive advantage.
In that context, the International Tennis Integrity Agency (ITIA) has moved to clarify its position on medication use in professional tennis, including the controversial topic of ADHD treatments.
ITIA CEO Karren Moorhouse addressed the issue on the Off Court with Greg Rusedski podcast, insisting that the organization’s Therapeutic Use Exemption (TUE) system is designed to be strict, transparent and focused on athlete welfare.
ITIA insists ADHD medication approvals are 'rigorous'
Moorhouse pushed back against the perception that ADHD medication is widely used across the sport, explaining that approvals require detailed medical confirmation and review by independent experts. The ITIA chief stressed that the goal is to allow players to receive necessary treatments while maintaining a fair competitive environment — a debate that has returned to the spotlight following Serena Williams’ comeback.
The topic has made headlines before. Former world No. 7 Fernando Verdasco was provisionally suspended in 2022 after testing positive for methylphenidate, later explaining that he had simply forgotten to renew his Therapeutic Use Exemption before obtaining a new one.
His case became one of the highest-profile examples of how even administrative errors involving approved medication can lead to anti-doping sanctions.
Speaking on the
Off Court with Greg Rusedski podcast, ITIA chief executive Karen Moorhouse pushed back against the perception that ADHD medication is widely used across professional tennis, describing that belief as inaccurate.
"I think there is a perception in the tennis world that a huge number of players are taking ADHD medications. That is absolutely not the case," Moorhouse said. "And actually, particularly with ADHD, the process for getting a TUE involves getting, I think it’s two experts to confirm that diagnosis. So again, making sure that that is really carefully managed."
Serena Williams played doubles at the Berlin Ladies Open, alongside Karolina Muchova, but they were defeated in the first round.
According to the ITIA chief, players seeking approval to use ADHD medication must first have their diagnosis independently confirmed by two medical experts before their application is reviewed by a specialist committee. Only after that process is completed can an exemption be granted, allowing an athlete to legally use medication that would otherwise appear on the prohibited list.
Moorhouse stressed that the objective is not only to maintain a level playing field, but also to protect athletes who genuinely require treatment for medical reasons. "The primary objective is to protect athlete health," she explained. "There needs to be a system that allows players to take treatments necessary for their health, while ensuring there is no abuse or use of substances intended to enhance performance."
She added that the combination of independent medical evaluations and committee oversight is designed to prevent misuse while ensuring players with legitimate diagnoses are not prevented from receiving the treatment they need.